Tropical diseases

GLIDE Launches Inaugural Awards for Disease Elimination

Retrieved on: 
Wednesday, April 14, 2021
Infectious diseases, Biotechnology, Pharmaceutical, Health, Infectious diseases, Medical specialties, Clinical medicine, Neglected tropical diseases, Tropical diseases, Helminthiases, Spirurida, Lymphatic filariasis, Mohammed bin Zayed Al Nahyan, Filariasis, Onchocerciasis

b'The Global Institute for Disease Elimination (GLIDE), a new Abu Dhabi-based global health Institute focused on eliminating infectious diseases of poverty, has launched The Falcon Awards for Disease Elimination, in a drive to discover and implement innovative approaches to disease elimination.\nFounded in 2019 by His Highness Sheikh Mohamed bin Zayed, Crown Prince of Abu Dhabi, and the Bill & Melinda Gates Foundation, GLIDE identifies the latest scientific, cultural, and global health knowledge and puts it into action with partners through programmes to advance disease elimination.\nThe Falcon Awards, which open for submissions online on 4th May 2021, invites Non-Governmental Organisations (NGOs), philanthropic foundations, coalitions or networks of Civil Society Organisations (CSOs), academic or research institutions, Public-Private Partnerships (PPP), and public or private sector institutions in endemic countries to submit proposals that aim to accelerate the elimination of one or more of GLIDE\xe2\x80\x99s four focus diseases: malaria, polio, lymphatic filariasis, and onchocerciasis.\nGLIDE is particularly seeking proposals which address cross-border, cross-disease, cross-programme, or cross-sector approaches to disease elimination.

Key Points: 
  • b'The Global Institute for Disease Elimination (GLIDE), a new Abu Dhabi-based global health Institute focused on eliminating infectious diseases of poverty, has launched The Falcon Awards for Disease Elimination, in a drive to discover and implement innovative approaches to disease elimination.\nFounded in 2019 by His Highness Sheikh Mohamed bin Zayed, Crown Prince of Abu Dhabi, and the Bill & Melinda Gates Foundation, GLIDE identifies the latest scientific, cultural, and global health knowledge and puts it into action with partners through programmes to advance disease elimination.\nThe Falcon Awards, which open for submissions online on 4th May 2021, invites Non-Governmental Organisations (NGOs), philanthropic foundations, coalitions or networks of Civil Society Organisations (CSOs), academic or research institutions, Public-Private Partnerships (PPP), and public or private sector institutions in endemic countries to submit proposals that aim to accelerate the elimination of one or more of GLIDE\xe2\x80\x99s four focus diseases: malaria, polio, lymphatic filariasis, and onchocerciasis.\nGLIDE is particularly seeking proposals which address cross-border, cross-disease, cross-programme, or cross-sector approaches to disease elimination.
  • Submissions should focus on the implementation of innovative ideas and established research which has a high potential to be catalytic, transformational, or genuinely novel in approach, or on operational research with prospects to provide solutions to existing disease elimination challenges.\nSimon Bland, Chief Executive Officer of GLIDE, commented: \xe2\x80\x9cAt GLIDE, we firmly believe in an integrated and collaborative approach to tackling infectious diseases of poverty.
  • The Falcon Awards for Disease Elimination will help advance and amplify these efforts.\xe2\x80\x9d\nFive winners will be announced later this year following a thorough evaluation by a jury panel comprised of esteemed global health experts.
  • Each winner will receive a sum of up to USD200,000 to fund and implement their unique solutions to disease elimination.\nFor more information on The Falcon Awards and how to enter, please visit: https://glideae.org/awards\nThe Falcon Awards - key dates:\nGLIDE is a new global health Institute, rooted in Abu Dhabi, focused on accelerating the elimination of four preventable diseases of poverty: currently malaria, polio, lymphatic filariasis, and river blindness, by 2030 and beyond.

First Digital Vaccine Card Service VaxYes Converts 10,000 COVID Vaccine Cards Into Digital Vaccine Certificates

Retrieved on: 
Wednesday, April 14, 2021
Medical specialties, Medicine, Health, Vaccines, Medical records, Passports, Tropical diseases, World Health Organization, International Certificate of Vaccination or Prophylaxis, Vaccine, COVID-19 vaccine

b'SAN MATEO, Calif., April 14, 2021 /PRNewswire/ -- GoGetVax , the country\'s first end-to-end COVID-19 vaccine technology platform, has successfully helped its first 10,000users convert their vaccine cards into secure digital vaccination certificates using its vaccine technology service VaxYes .

Key Points: 
  • b'SAN MATEO, Calif., April 14, 2021 /PRNewswire/ -- GoGetVax , the country\'s first end-to-end COVID-19 vaccine technology platform, has successfully helped its first 10,000users convert their vaccine cards into secure digital vaccination certificates using its vaccine technology service VaxYes .
  • GoGet, Inc.is the parent company of GoGetVax.
  • "\nUsers convert paper vaccine cards into digital vaccine certificates by visiting the VaxYes page, providing their phone number, uploading photos of their vaccination card and ID, and receiving their digital vaccine certificate upon verification.
  • GoGetVax\'s COVID-19 response units ensure geographical reach to rural areas and fast activation in virus hotspots.

VaxAtlas Launches App To Record, Store and Share COVID Vaccination Records

Retrieved on: 
Tuesday, April 13, 2021
Vaccines, Medical records, Passports, Tropical diseases, World Health Organization, Medical specialties, International Certificate of Vaccination or Prophylaxis, Vaccination, Articles, Health

b'BOSTON, April 13, 2021 /PRNewswire/ -- VaxAtlas , the leading software and vaccine management platform, today launched the VaxAtlas app, available for iOS and Android.

Key Points: 
  • b'BOSTON, April 13, 2021 /PRNewswire/ -- VaxAtlas , the leading software and vaccine management platform, today launched the VaxAtlas app, available for iOS and Android.
  • The VaxAtlas app provides consumers with a digital and portable solution to securely store vaccination cards, organize vaccination records, receive alerts and booster notifications, then verify and share with any verification pass or organization when needed.
  • Through the VaxAtlas app, users can eliminate forgotten or lost paperwork by scanning CDC paper records, easily retrieve digitized vaccination cards and access a lifetime storage solution.
  • Through a combination of vaccination information, claims data and national records, VaxAtlas prevents fraudulent records by verifying vaccination records as well as the user.

Sandia International Launches more Secure, Private Vaccine Pass Technology

Retrieved on: 
Friday, April 16, 2021
Passports, Medical specialties, Articles, Medicine, Medical records, Tropical diseases, World Health Organization, Immunology, International Certificate of Vaccination or Prophylaxis, QR code, Immunity passport, Tamperproofing

b'GRAND PRAIRIE, Texas, April 16, 2021 /PRNewswire/ --A first-of-its-kind, secure SMART Health Card solution that stores encrypted vaccination records and identity authenticators is now available from Sandia International, Inc., a secure identification technology provider based in North Texas.

Key Points: 
  • b'GRAND PRAIRIE, Texas, April 16, 2021 /PRNewswire/ --A first-of-its-kind, secure SMART Health Card solution that stores encrypted vaccination records and identity authenticators is now available from Sandia International, Inc., a secure identification technology provider based in North Texas.
  • The card\'s underlying technology is SecuSeal , a proprietary solution that is similar to a QR-code but more intricately encoded, private, tamper-proof, and secure.
  • This new vaccination credential can be accessed and validated digitally, online, and offline.
  • Domestically, even if not required, a vaccine passport could exempt cardholders from strict testing and quarantine requirements.

VaccineCheck Provides Secure and Accessible Digital Vaccine Passport to Support Safe Return to Work, Travel and Normalcy

Retrieved on: 
Wednesday, March 31, 2021
Passports, Medical specialties, Health, Medicine, Immunology, Medical records, Tropical diseases, World Health Organization, Immunity passport, International Certificate of Vaccination or Prophylaxis, Identity document

VaccineCheck is now being used by local governments in Maryland and New York.

Key Points: 
  • VaccineCheck is now being used by local governments in Maryland and New York.
  • Users can register themselves and their families on the VaccineCheck site and businesses can launch secure staff vaccine passports.
  • Designed to "go where you go," the VaccineCheck digital health passport is stored in a HIPAA-compliant cloud environment following registration, which entails verification of vaccination by a medical professional.
  • Ahead of COVID-19, WellCheck's HIPAA-compliant mobile device health exchange platform enabled remote wellness visits, essential safety screening and secure communication in an emergency situation.

GHIT Fund Announces New Investments: A Total of 2.3 Billion Yen in Drugs for Malaria, Tuberculosis, Chagas Disease and Visceral Leishmaniasis, Vaccine for Malaria and Diagnostics for Tuberculosis

Retrieved on: 
Wednesday, March 31, 2021
Medical specialties, Infectious diseases, Malaria, Clinical medicine, Tropical diseases, Epidemiology, Vaccination, Malaria vaccine, Vaccines, Antimalarial medication, Vaccine, Parasitism

Targeted vaccination of individuals in high transmission areas promise an immediate and effective reduction in the number of malaria cases.

Key Points: 
  • Targeted vaccination of individuals in high transmission areas promise an immediate and effective reduction in the number of malaria cases.
  • Although a TBV would not directly prevent immunized individuals from developing the disease, it has a clear, delayed clinical benefit for the population.
  • Moreover, a TBV could provide effective means to prevent the spread of antimalarial drug-resistant parasites, and parasites that break through the most advanced malaria vaccine (Mosquirix) to date.
  • Thus, the development of new TBVs is one of the research priorities for a cost-effective intervention that can directly support the malaria eradication effort.

Press release - MEPs demand safe and clean travel

Retrieved on: 
Friday, March 26, 2021
Articles, Organizations, Medical records, Passports, Tropical diseases, World Health Organization, Value-added tax, European Union, International Certificate of Vaccination or Prophylaxis, Sustainable tourism, Tourism

MEPs highlight that the tourism and travel sectors account for around 10% of the EUs GDP.

Key Points: 
  • MEPs highlight that the tourism and travel sectors account for around 10% of the EUs GDP.
  • They therefore urge EU countries to include them in their recovery plans and to consider temporarily reducing VAT on these services.
  • Safe and clean tourism

    Due to the pandemic, travellers want safe, clean and more sustainable tourism, Parliament says, calling on member states to fully implement common criteria for safe travel without delay.

  • A common vaccination certificate should facilitate travel and act as an alternative to PCR tests and quarantine requirements, MEPs say.

KM Biologics Announces Phase I Clinical Study Results of a Live Attenuated Tetravalent Dengue Vaccine (KD-382)

Retrieved on: 
Thursday, March 25, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medical specialties, Infectious diseases, Clinical medicine, Dengue fever, Virology, Neglected tropical diseases, Tropical diseases, Vaccination, Dengue vaccine, Dengue virus, Mosquito-borne disease, Vaccine

KM Biologics Co., Ltd. (Headquarters: Kumamoto, Japan; CEO: Toshiaki Nagasato) announced the results of the Phase I clinical study (hereinafter the Study) of a live attenuated tetravalent vaccine, KD-382*1 (hereinafter, the KD-382 vaccine), to prevent dengue*2.

Key Points: 
  • KM Biologics Co., Ltd. (Headquarters: Kumamoto, Japan; CEO: Toshiaki Nagasato) announced the results of the Phase I clinical study (hereinafter the Study) of a live attenuated tetravalent vaccine, KD-382*1 (hereinafter, the KD-382 vaccine), to prevent dengue*2.
  • The results show that the KD-382 vaccine is safe and well-tolerated by healthy adults.
  • KD-382 is a live attenuated tetravalent dengue vaccine that is expected to be effective against all four serotypes with a single dose.
  • Dengue virus is a mosquito-borne virus belonging to the Flaviviridae family and causes dengue fever, dengue hemorrhagic fever, and dengue shock syndrome in humans.

CDC Foundation Supports Guinea and the Democratic Republic of the Congo to Take on Latest Ebola Outbreaks in Both Nations

Retrieved on: 
Monday, March 22, 2021
Medical specialties, Infectious diseases, Continents, West African Ebola virus epidemic, Biological weapons, Tropical diseases, Zoonoses, Bat virome, Ebola, Democratic Republic of the Congo

At the same time, another Ebola outbreak is continuing in the Democratic Republic of the Congo (DRC).

Key Points: 
  • At the same time, another Ebola outbreak is continuing in the Democratic Republic of the Congo (DRC).
  • "Right now, it is critical to take steps to strengthen the responses in Guinea and DRC," said Judy Monroe, MD, president and CEO of the CDC Foundation.
  • In Guinea, the CDC Foundation is assisting with an urgent and timely request to support Agence Nationale de Scurit Sanitaire (ANSS) which is part of the Ministry of Health.
  • The CDC Foundation managed hundreds of CDC-led programs in the United States and in more than 140 countries last year.

WISeKey Launches Digital Vaccination Certificates Platform VaccineTrusts.com, to be Used as a Proof of Evidence for Those Who Have Received Coronavirus Vaccine

Retrieved on: 
Monday, March 15, 2021
Medical specialties, Medicine, Passports, Health, Vaccines, Vaccination, Medical records, Tropical diseases, International Certificate of Vaccination or Prophylaxis, Immunity passport, Vaccine, COVID-19 vaccine

The VaccineTrusts integrates Digital Vaccination Certificates (DVC) issued by different third trusted parties and is to be used as a proof of evidence for those who have received the coronavirus vaccines.

Key Points: 
  • The VaccineTrusts integrates Digital Vaccination Certificates (DVC) issued by different third trusted parties and is to be used as a proof of evidence for those who have received the coronavirus vaccines.
  • Vaccine passports, also known as vaccine certificates, have been recently and important vaccine verification solution as countries worldwide roll out their mass vaccination programs.
  • The International Air Transport Association (IATA) has called for a global standard to securely record digital proof of vaccination.
  • WISeKey has been already selected by the International Air Transport Association (IATA) as its technology partner to secure the ONE Record test platform.